HV PHARMACY, INC.
COCKEYSVILLE, MD

Mr. Askew co-owns HV PharmaLabs & HV Pharmacy, Inc. (“HVP”) with Brian H. Trentler, R.Ph. HVP is a 33-year provider of custom, branded, and generic medications to patients and physician practices in the mid-Atlantic region. Focusing on providing custom sterile medications and biologics for ophthalmology, HVP operates as a high-quality manufacturer of customized medications and biological therapies. HVP owns the brands NovoTears™, OP Drops™, and Stat Drops™. Prior to TBI, Mr. Askew was President/CEO and Chairman of CSA Medical, Inc., a privately held medical device technology company dedicated to pioneering the TruFreezeTM platform to eradicate pre-cancerous and cancerous tissues. TruFreeze is a patented treatment platform currently in use at the top cancer centers in the US. At CSA Medical, Mr. Askew has raised over $20 million of private equity capital and led the company through numerous regulatory, clinical, product development, staffing, and commercialization milestones. CSA Medical is currently commercializing a novel therapy to treat chronic bronchitis. While at Johns Hopkins, Mr. Trentler co-authored two papers: (1) Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose, and (2) Does Intraoperative Blood Loss Affect Antibiotic Serum and Tissue Concentrations? Mr. Trentler also provided numerous nursing continuing education seminars and presented a novel antibiotic dosing strategy to the surgical intensive care unit’s resident staff. In 2001 Mr. Trentler became a Clinical Manager for CVS Caremark. In this role, he worked with Fortune 500 companies such as Proctor & Gamble, Comcast, and Wendy’s to implement employee pharmacy benefits. This position required both quarterly and annual objectives to provide and analyze data regarding customers’ drug spending and utilization along with proactive cost containment strategies. In 2004, Mr. Trentler became co-owner of Hunt Valley Pharmacy. His passion is developing and introducing product and service offerings to improve customer satisfaction, health, and loyalty. Custom compounding, the cornerstone of Hunt Valley Pharmacy’s business, has grown significantly over the past 11 years. In 2014 Mr. Trentler partnered with Mr. Tim Askew to introduce sterile compounding to compliment successful non-sterile compounding product lines as Hunt Valley PharmaLabs. Since 2011, Mr. Trentler has served on Maryland Medicaid’ Drug Utilization Review Board & Corrective Managed Care Advisory Committee. The Drug Utilization Board works to optimize patient outcomes by balancing cost effective treatment modalities. The Corrective Managed Care Advisory Committee investigates reports of fraud and abuse within Maryland Medicare programs saving taxpayer money and ensuring integrity amongst providers. Through our procedures and practices we are considered a 503A pharmacy as defined by the US Food and Drug Administration (“FDA”). Specifically, we produce custom non-sterile and sterile medications on an individual patient basis, by prescription, or in anticipation of such based on dispensing history. Through our procedures and practices we are considered a 503A pharmacy as defined by the US Food and Drug Administration (“FDA”). Specifically, we produce custom non-sterile and sterile medications on an individual patient basis, by prescription, or in anticipation of such based on dispensing history. Through our procedures and practices we are considered a 503A pharmacy as defined by the US Food and Drug Administration (“FDA”). Specifically, we produce custom non-sterile and sterile medications on an individual patient basis, by prescription, or in anticipation of such based on dispensing history.